CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent antitumor effects in B-cell malignancies including acute lymphoblastic leukemia (ALL), but antigen loss remains the major cause of treatment failure. To mitigate antigen escape and potentially improve the durability of remission,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2022-04, Vol.36 (4), p.1015-1024
Hauptverfasser:	Wang, Xiuli, Dong, Zhenyuan, Awuah, Dennis, Chang, Wen-Chung, Cheng, Wesley A., Vyas, Vibhuti, Cha, Soung-Chul, Anderson, Aaron J., Zhang, Tiantian, Wang, Zhe, Szymura, Szymon J., Kuang, Benjamin Z., Clark, Mary C., Aldoss, Ibrahim, Forman, Stephen J., Kwak, Larry W., Qin, Hong
Format:	Artikel
Sprache:	eng
Schlagworte:	13 13/1 13/106 13/21 13/31 42/44 59/5 631/250/251 631/67/1059/2325 64/60 692/308/575 Acute lymphoblastic leukemia Animals Anticancer properties Antigens Antigens, CD19 Antitumor activity Biocompatibility BLyS protein Cancer Research CD19 antigen Chimeric antigen receptors Critical Care Medicine Cytokines Cytotoxicity Degranulation Durability Hematology Humans Immunodeficiency Immunotherapy, Adoptive Intensive Internal Medicine Leukemia Lymphatic leukemia Lymphocytes Lymphocytes B Lymphocytes T Medicine Medicine & Public Health Mice Oncology Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Receptors, Chimeric Antigen - genetics Remission T-Lymphocytes Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!